PARKINSON'S DISEASE SOCIETY OF THEUNITED KINGDOM LBG

Their core work

Parkinson's UK is the largest Parkinson's charity in the UK, funding research, providing support services, and advocating for people living with Parkinson's disease. In the H2020 context, they bring the patient perspective and disease-specific expertise into large-scale neurodegenerative disease research consortia, spanning areas from mitochondrial biology to digital health monitoring. They contribute domain knowledge on disease burden, patient needs, regulatory engagement, and health technology assessment — bridging the gap between laboratory research and real-world patient outcomes.

What they specialise in

How they've shifted over time

All four of Parkinson's UK's H2020 projects started in 2019, making a temporal evolution analysis limited. However, the keyword distribution shows a shift from programme-level activities (portfolio management, sustainability, regulatory engagement, data sharing) toward clinical and translational topics (nicotinic agonists, biomarkers, imaging, digital endpoints for fatigue and sleep). This suggests a move from infrastructure and governance roles toward direct involvement in clinical research and digital health measurement.

Parkinson's UK is moving toward digital health tools and translational biomarker research, making them a strong partner for projects combining patient engagement with digital monitoring technologies.

How they like to work

Parkinson's UK exclusively participates as a consortium partner rather than leading projects, which is typical for patient organizations that contribute disease expertise and patient advocacy rather than managing research infrastructure. With 80 unique partners across 20 countries from just 4 projects, they operate in large, international consortia — likely IMI (Innovative Medicines Initiative) and similar public-private partnerships. This broad network makes them a well-connected entry point into the European Parkinson's and neurodegeneration research landscape.

With 80 unique consortium partners across 20 countries from only 4 projects, Parkinson's UK sits within large-scale European research networks — averaging 20 partners per consortium. Their reach spans most of Europe, reflecting the multinational nature of IMI-style neurodegeneration initiatives.

What sets them apart

As the UK's leading Parkinson's charity, they bring something most research partners cannot: direct access to the patient community, deep understanding of disease burden, and credibility with regulators and HTA bodies. For consortium builders, adding Parkinson's UK means gaining a patient-focused partner with established connections to both the clinical world and the IMI neurodegeneration ecosystem. Their involvement signals strong patient and public involvement (PPI), which is increasingly required by EU funders.

Highlights from their portfolio

• IDEA-FAST
  Ambitious 7-year project (2019-2026) developing digital endpoints across neurodegenerative and inflammatory diseases — signals long-term commitment to digital health innovation.
• NEURONET
  A coordination and support action networking the entire IMI neurodegeneration portfolio, giving Parkinson's UK visibility across multiple major EU brain research initiatives.
• PD-MIND
  Directly targets Parkinson's cognitive impairment with a specific drug candidate (nicotinic agonist), representing a concrete therapeutic intervention rather than basic research.